arrow
A

Antonino Belfiore

Fondazione IRCCS Istituto Nazionale dei Tumori
H指数:18
被引数:1,032

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO

曲美木单抗和度伐利尤单抗作为微卫星不稳定性高、可切除的胃或胃食管结合部腺癌患者的新辅助治疗或非手术治疗策略:GONO开展的INFINITY研究

2025-03-018
PRE
Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor-Targeted Therapy Drives Resistance in Breast Cancer
2024-10-020
PRE
Modulation of systemic and intratumor metabolism predicts response to fasting-mimicking diet plus chemotherapy in patients with early TNBC

系统性及肿瘤内代谢的调控预测了空腹模拟饮食联合化疗对早期TNBC患者的反应

2024-09-010
PRE
Precocious modulation of metabolic and immunological parameters predicts tumor response to fastingmimicking diet plus chemotherapy in patients with early stage TNBC
2024-05-021
PRE
Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trial
2023-08-248
OAAI
Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab
2022-07-0515
OA
High CD36 expression predicts worse event free survival in HER2-positive breast cancer patients treated with neoadjuvant trastuzumab-based therapy: An exploratory analysis of the NeoALTTO study
2022-02-151
PRE
Fasting- Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer
2021-11-17170
OAAI
Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials
2020-08-0117
PREAI